Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Artiva Biotherapeutics Inc. (ARTV) Insider Trading Activity
Healthcare • Biotechnology • 82 employees
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Total Value
$0.00
Total Shares
300,000
Average Trade Value
$0.00
Most Active Insider
Raymon Heather
Total Activity: $0
Largest Single Transaction
$0
by Raymon Heather on Feb 26, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Svp, Research and Development
|
Feb 26, 2025 | 33,350 | $0 | 43,350 (+76.9%) | Grant | |
|
Coo, Clo, Secy, Compliance Off
|
Feb 26, 2025 | 86,650 | $0 | 159,449 (+54.3%) | Grant | |
|
Chief Financial Officer
|
Feb 26, 2025 | 60,000 | $0 | 110,000 (+54.5%) | Grant | |
|
Chief Medical Officer
|
Feb 26, 2025 | 60,000 | $0 | 80,000 (+75.0%) | Grant | |
|
Chief Tech Operations Officer
|
Feb 26, 2025 | 60,000 | $0 | 85,000 (+70.6%) | Grant |